돌루테그라비르/라미부딘/테노포비르 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "돌루테그라비르/라미부딘/테노포비르" in Korean language version.

refsWebsite

Global rank Korean rank

102^nd place

307^th place

447^th place

433^rd place

195^th place

98^th place

1web.archive.org

1^st place

1^st place

1medicinespatentpool.org

low place

low place

2^nd place

3^rd place

4^th place

4^th place

1semanticscholar.org

11^th place

310^th place

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Vitoria, M; Hill, A; Ford, N; Doherty, M; Clayden, P; Venter, F; Ripin, D; Flexner, C; Domanico, PL (2018년 7월 31일). “The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?”. 《AIDS》 32 (12): 1551–61. doi:10.1097/QAD.0000000000001845. PMID 29746295. S2CID 13674631.

fda.gov (Global: 447^th place; Korean: 433^rd place)

accessdata.fda.gov

“NDA 209618 Tentative Approval” (PDF). 《U.S. Food and Drug Administration (FDA)》. 2019년 3월 25일. 2019년 11월 16일에 확인함.
“NDA 210796 Tentative Approval” (PDF). 《U.S. Food and Drug Administration (FDA)》. 2017년 8월 18일.

handle.net (Global: 102^nd place; Korean: 307^th place)

hdl.handle.net

World Health Organization (2019). “Policy brief: update of recommendations on first- and second-line antiretroviral regimens”. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

medicinespatentpool.org (Global: low place; Korean: low place)

“TDF/3TC/DTG” (PDF). 2019년 11월 16일에 확인함.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

Vitoria, M; Hill, A; Ford, N; Doherty, M; Clayden, P; Venter, F; Ripin, D; Flexner, C; Domanico, PL (2018년 7월 31일). “The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?”. 《AIDS》 32 (12): 1551–61. doi:10.1097/QAD.0000000000001845. PMID 29746295. S2CID 13674631.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Vitoria, M; Hill, A; Ford, N; Doherty, M; Clayden, P; Venter, F; Ripin, D; Flexner, C; Domanico, PL (2018년 7월 31일). “The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?”. 《AIDS》 32 (12): 1551–61. doi:10.1097/QAD.0000000000001845. PMID 29746295. S2CID 13674631.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“WHO-PQ Recommended summary of product characteristics” (PDF). July 2019. 2019년 11월 16일에 원본 문서 (PDF)에서 보존된 문서. 2019년 11월 16일에 확인함.

who.int (Global: 195^th place; Korean: 98^th place)

who.int

“Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD)” (PDF). 《World Health Organization (WHO)》. 2019년 11월 15일에 확인함.

extranet.who.int

“WHO-PQ Recommended summary of product characteristics” (PDF). July 2019. 2019년 11월 16일에 원본 문서 (PDF)에서 보존된 문서. 2019년 11월 16일에 확인함.